Spero Therapeutics, Inc. (SPRO)
After hours:
| Previous close | 1.2000 |
| Open | 1.2100 |
| Bid | 1.2200 x 1200 |
| Ask | 1.2700 x 900 |
| Day's range | 1.2000 - 1.2800 |
| 52-week range | 1.1700 - 19.8700 |
| Volume | |
| Avg. volume | 665,666 |
| Market cap | 40.699M |
| Beta (5Y monthly) | 1.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206’s Phase 1 Data Support Further Development in Complicated Urinary Tract Infection, Hospital-acquired and Ventilator-associated Bacterial Pneumonia, and Bloodstream Infections Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., May
- GlobeNewswire
Spero Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Ma
- GlobeNewswire
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13729221. The audio webcast can be accessed under “Events and Presentat
